Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mammaplasty | 3 | 2021 | 47 | 1.280 |
Why?
|
| Breast Neoplasms | 9 | 2021 | 1216 | 1.100 |
Why?
|
| Mastectomy, Segmental | 4 | 2021 | 46 | 0.820 |
Why?
|
| Mastectomy | 4 | 2020 | 56 | 0.810 |
Why?
|
| Surgical Flaps | 2 | 2021 | 116 | 0.660 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2016 | 12 | 0.490 |
Why?
|
| Thyroidectomy | 3 | 2017 | 31 | 0.450 |
Why?
|
| Recurrent Laryngeal Nerve | 1 | 2013 | 4 | 0.410 |
Why?
|
| Glottis | 1 | 2013 | 7 | 0.400 |
Why?
|
| Vocal Cord Paralysis | 1 | 2013 | 10 | 0.400 |
Why?
|
| Monitoring, Intraoperative | 1 | 2013 | 47 | 0.400 |
Why?
|
| Thyroid Neoplasms | 4 | 2017 | 77 | 0.400 |
Why?
|
| Recovery of Function | 1 | 2013 | 290 | 0.350 |
Why?
|
| Postoperative Complications | 3 | 2019 | 1310 | 0.220 |
Why?
|
| Lymph Nodes | 2 | 2017 | 232 | 0.220 |
Why?
|
| Organ Size | 1 | 2021 | 171 | 0.170 |
Why?
|
| Anatomic Variation | 1 | 2020 | 7 | 0.160 |
Why?
|
| Thoracic Wall | 1 | 2020 | 21 | 0.160 |
Why?
|
| Nipples | 1 | 2019 | 12 | 0.150 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 17 | 0.150 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2019 | 44 | 0.150 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 100 | 0.140 |
Why?
|
| Prognosis | 4 | 2019 | 1777 | 0.140 |
Why?
|
| Neck Dissection | 2 | 2017 | 18 | 0.140 |
Why?
|
| Lymphatic Metastasis | 3 | 2017 | 91 | 0.130 |
Why?
|
| Female | 13 | 2021 | 33771 | 0.130 |
Why?
|
| Middle Aged | 10 | 2021 | 18122 | 0.130 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 2484 | 0.130 |
Why?
|
| Intraoperative Care | 2 | 2016 | 38 | 0.130 |
Why?
|
| Breast Implants | 1 | 2016 | 14 | 0.120 |
Why?
|
| Humans | 18 | 2021 | 64796 | 0.120 |
Why?
|
| Carcinoma | 1 | 2017 | 130 | 0.120 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 50 | 0.120 |
Why?
|
| Gestational Age | 1 | 2016 | 195 | 0.120 |
Why?
|
| Retrospective Studies | 6 | 2019 | 6801 | 0.110 |
Why?
|
| Muscle, Skeletal | 1 | 2020 | 764 | 0.110 |
Why?
|
| Carcinoma, Papillary | 2 | 2017 | 37 | 0.110 |
Why?
|
| Breast Neoplasms, Male | 1 | 2014 | 14 | 0.110 |
Why?
|
| Thyroid Nodule | 1 | 2014 | 15 | 0.110 |
Why?
|
| Adult | 9 | 2019 | 17246 | 0.110 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2014 | 56 | 0.110 |
Why?
|
| Multimodal Imaging | 1 | 2014 | 73 | 0.100 |
Why?
|
| Thyroid Gland | 1 | 2014 | 82 | 0.100 |
Why?
|
| Vocal Cords | 1 | 2013 | 5 | 0.100 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2014 | 91 | 0.100 |
Why?
|
| Postoperative Period | 1 | 2013 | 130 | 0.100 |
Why?
|
| Electromyography | 1 | 2013 | 98 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 205 | 0.100 |
Why?
|
| Breast Diseases | 1 | 2013 | 45 | 0.100 |
Why?
|
| Operative Time | 1 | 2013 | 91 | 0.100 |
Why?
|
| Radiographic Image Enhancement | 1 | 2013 | 98 | 0.100 |
Why?
|
| Laryngoscopy | 1 | 2013 | 61 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 369 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 2240 | 0.090 |
Why?
|
| Mammography | 1 | 2013 | 290 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2016 | 2608 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2016 | 3303 | 0.080 |
Why?
|
| Lymph Node Excision | 1 | 2009 | 44 | 0.080 |
Why?
|
| Pregnancy | 1 | 2016 | 2361 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2016 | 5757 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 156 | 0.070 |
Why?
|
| Young Adult | 5 | 2017 | 4777 | 0.070 |
Why?
|
| Antigens, Neoplasm | 1 | 2008 | 129 | 0.070 |
Why?
|
| Neoplasms, Experimental | 1 | 2008 | 77 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2008 | 203 | 0.070 |
Why?
|
| Neoplasm Staging | 3 | 2015 | 534 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 141 | 0.060 |
Why?
|
| Supine Position | 2 | 2017 | 33 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2009 | 352 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 371 | 0.060 |
Why?
|
| Neoplasms | 2 | 2014 | 1360 | 0.060 |
Why?
|
| Epigenesis, Genetic | 1 | 2008 | 405 | 0.060 |
Why?
|
| Aged | 6 | 2017 | 14848 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 462 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2008 | 1029 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 706 | 0.050 |
Why?
|
| Incidental Findings | 1 | 2020 | 49 | 0.040 |
Why?
|
| Cell Line, Tumor | 3 | 2009 | 1558 | 0.040 |
Why?
|
| Prone Position | 1 | 2017 | 28 | 0.030 |
Why?
|
| Perioperative Care | 1 | 2017 | 86 | 0.030 |
Why?
|
| Patient Positioning | 1 | 2016 | 50 | 0.030 |
Why?
|
| Adolescent | 2 | 2017 | 6293 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 94 | 0.030 |
Why?
|
| Oleic Acid | 1 | 2014 | 20 | 0.030 |
Why?
|
| Demography | 1 | 2015 | 179 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2014 | 76 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2014 | 66 | 0.030 |
Why?
|
| Probability | 1 | 2014 | 168 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 285 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 1105 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2015 | 201 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2014 | 196 | 0.020 |
Why?
|
| Disease Management | 1 | 2015 | 233 | 0.020 |
Why?
|
| Efficiency, Organizational | 1 | 2013 | 92 | 0.020 |
Why?
|
| Recurrence | 1 | 2014 | 659 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2014 | 579 | 0.020 |
Why?
|
| Lipids | 1 | 2014 | 326 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 5575 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 989 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2014 | 1002 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 523 | 0.020 |
Why?
|
| Thyroglobulin | 1 | 2009 | 9 | 0.020 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2009 | 17 | 0.020 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2009 | 17 | 0.020 |
Why?
|
| Polycomb-Group Proteins | 1 | 2009 | 21 | 0.020 |
Why?
|
| Smoke | 1 | 2009 | 24 | 0.020 |
Why?
|
| Sirtuins | 1 | 2009 | 26 | 0.020 |
Why?
|
| Sirtuin 1 | 1 | 2009 | 27 | 0.020 |
Why?
|
| Acetylation | 1 | 2009 | 120 | 0.020 |
Why?
|
| Male | 3 | 2017 | 30812 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2009 | 104 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2009 | 287 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2009 | 241 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2009 | 324 | 0.020 |
Why?
|
| Cysteine | 1 | 2008 | 107 | 0.020 |
Why?
|
| Thalidomide | 1 | 2008 | 33 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2008 | 84 | 0.020 |
Why?
|
| Pyrroles | 1 | 2008 | 49 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2008 | 384 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2008 | 236 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2009 | 489 | 0.020 |
Why?
|
| Indoles | 1 | 2008 | 111 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2008 | 268 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2008 | 202 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 2679 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2009 | 302 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2008 | 279 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2008 | 204 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 682 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2008 | 267 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 794 | 0.010 |
Why?
|
| Mice | 2 | 2009 | 11085 | 0.010 |
Why?
|
| Peptides | 1 | 2008 | 588 | 0.010 |
Why?
|
| Cytokines | 1 | 2008 | 952 | 0.010 |
Why?
|
| Rats | 1 | 2008 | 1997 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 1007 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2009 | 1220 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2009 | 969 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2008 | 904 | 0.010 |
Why?
|
| United States | 1 | 2015 | 8036 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2009 | 1549 | 0.010 |
Why?
|
| Animals | 2 | 2009 | 21297 | 0.010 |
Why?
|
| Risk Factors | 1 | 2009 | 5396 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2009 | 3148 | 0.010 |
Why?
|